I am the driving force behind Tribune Updates with a vision to broaden the company’s readership throughout 2016. I am an editor and reporter of “Healthcare” category.
Address: 1208 Jewell Road Eagan, MN 55121, USA
Phone: (+1) 612-598-3663
Latest posts by Richard Bower (see all)
- Active Stock’s Momentum: Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) - November 15, 2019
- Earnings Recap: Cutera Inc. (NASDAQ: CUTR) - November 13, 2019
- Earnings Alert: CytomX Therapeutics Inc. (NASDAQ: CTMX) - November 13, 2019
MONMOUTH JUNCTION, N.J., November 13, 2019 – Shares of Cytosorbents Corporation (NASDAQ: CTSO) lost -0.68% to $4.39. The stock traded total volume of 178.409K shares lower than the average volume of 179.88K shares.
CytoSorbents Corporation (CTSO) reported total Q2 2019 revenues of $6.20M, including both product sales and grant income, an increase of approximately 8% from $5.80M in Q2 2018.
Product sales for Q2 2019 were approximately $5.90M, compared to $5.20M for Q2 2018, an increase of approximately 12%. Q2 2019 product sales would have been approximately $6.20M, or $357.0K (18%) higher than a year ago, had the Euro remained unchanged. Strong cash position with $16.3M at the end of the quarter, and approximately $20.0M at the end of July, reflecting the additional proceeds from debt.
CTSO has the market capitalization of $138.94M and its EPS growth ratio for the past five years was 5.60%. The return on assets ratio of the Company was -67.70% while its return on investment ratio stands at -55.60%. Price to sales ratio was 5.89 while 25.90% of the stock was owned by institutional investors.